Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001377028 | SCV001574253 | likely pathogenic | Granulomatous disease, chronic, X-linked | 2020-09-03 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the c.252+5G nucleotide in the CYBB gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 29560547, 1520880, 20729109). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with clinical features of chronic granulomatous disease (PMID: 9585602, 11162142, 27980538, 20729109, Invitae). This variant is also known as intron 3 gtaag>gtaac. This variant is not present in population databases (ExAC no frequency). This sequence change falls in intron 3 of the CYBB gene. It does not directly change the encoded amino acid sequence of the CYBB protein, but it affects a nucleotide within the consensus splice site of the intron. |
| Clinic of Clinical Immunology with Stem Cell Bank, |
RCV001377028 | SCV002573418 | likely pathogenic | Granulomatous disease, chronic, X-linked | 2022-05-01 | no assertion criteria provided | clinical testing |